Financing, Equity Capital Markets

Fate Therapeutics, Inc.

12/17
|
$46.0 Million
Piper selected as bookrunner for Fate Therapeutics on a confidentially marketed follow-on offering
Sub-Type
CMFO
Sub-Sector
Healthcare Services